1.44

0.00% +0.00

After Hours: 1.5055 0.0655 +4.55%

Imunon Inc (IMNN)

Overview News Price History Discussions Forecast Stock Split

Imunon Inc stock is currently priced at $1.44, with a 24-hour trading volume of 48,470. It has seen a +0.00% increased in the last 24 hours and a +23.17% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.38 pivot point. If it approaches the $1.50 resistance level, significant changes may occur.

Previous Close:

$1.44

Open:

$1.45

24h Volume:

48,470

Market Cap:

$13.54M

Revenue:

$500.00K

Net Income/Loss:

$-19.52M

P/E Ratio:

-0.382

EPS:

-3.77

Net Cash Flow:

$-19.47M

1W Performance:

+23.08%

1M Performance:

+23.17%

6M Performance:

+42.57%

1Y Performance:

+25.76%

1D Range:

$1.3801

$1.4754

52W Range:

$0.48

$2.00

Imunon Inc Stock (IMNN) Company Profile

Name

Imunon Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

609 896 9100

Address

997 Lenox Drive, Suite 100, Lawrenceville

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

IMNN's Discussions on Twitter

Imunon Inc Stock (IMNN) Latest News

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

GlobeNewswire Inc.

IMUNON Announces Leadership Change

GlobeNewswire Inc.

Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

GlobeNewswire Inc.

Imunon Inc Stock (IMNN) Financials Data

Imunon Inc (IMNN) Revenue 2024

IMNN reported a revenue (TTM) of $500.00 thousand for the quarter ending December 31, 2022, a 0.00% decline year-over-year.

Imunon Inc (IMNN) Net Income 2024

IMNN net income (TTM) was -$19.52 million for the quarter ending December 31, 2023, a +45.64% increase year-over-year.

Imunon Inc (IMNN) Cash Flow 2024

IMNN recorded a free cash flow (TTM) of -$19.47 million for the quarter ending December 31, 2023, a +16.65% increase year-over-year.

Imunon Inc (IMNN) Earnings per Share 2024

IMNN earnings per share (TTM) was -$2.18 for the quarter ending December 31, 2023, a +57.83% growth year-over-year.

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.